This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

First Patient Enrolled In Boston Scientific Randomized Study Comparing WallFlex® Biliary RX Stent To Absence Of Biliary Drainage In Patients With Pancreatic Or Periampullary Cancers

NATICK, Mass., May 15, 2013 /PRNewswire/ -- The first patient has been enrolled in a clinical investigation evaluating the use of the Boston Scientific Corporation (NYSE: BSX) WallFlex® Biliary RX Stent, a self-expanding metal stent (SEMS), as a bridge to surgery compared with the absence of drainage prior to surgery.  This multi-center, prospective, randomized study is expected to enroll 294 patients at leading hospitals in Australia, Belgium, Canada, France, Hong Kong, India, Italy and Japan.  The first patient was enrolled by Professor Jacques Deviere of Erasme Hospital in Brussels.

"Patients with pancreatic or periampullary cancer often have high levels of bilirubin, which adversely affect their liver, cardiovascular and renal functions," said Professor Deviere.  "These patients often have impaired immune response and clotting, which in turn could negatively impact the outcome of their surgical resection.  Preoperative biliary drainage could potentially reverse these factors and therefore result in an improved outcome of the surgery.  Published data regarding plastic stent drainage prior to surgical resection have been unfavorable and physicians are increasingly turning to self-expanding metal stents for preoperative drainage where necessary due to their large diameter.  We expect this study to provide us with important data on the safety and effectiveness of this approach compared with proceeding to surgery without biliary drainage."

SEMS have long been considered the standard of care for the palliative treatment of malignant biliary strictures.  This study evaluates the benefits of using SEMS in preoperative settings, with an objective of documenting clinical safety and effectiveness as compared to the standard, direct-to-surgery approach.

"Boston Scientific is committed to advancing science through investment in robust clinical research, while delivering innovative technologies designed to improve quality of life for patients," said David Pierce, president, Endoscopy, Boston Scientific.  "The results of this study may indicate that using SEMS preoperatively for biliary drainage could result in better patient outcomes and prove to be more cost effective for physicians and hospitals."

The study includes WallFlex Biliary Fully Covered and Uncovered Metal Stents.  The WallFlex Biliary Fully Covered Stent has a silicone polymer Permalume® Coating designed to reduce the potential for tumor/tissue ingrowth, and an integrated retrieval loop for removing or repositioning the stent in the event of incorrect placement during the initial procedure or for removal from benign strictures up to one year after placement.  The stent is constructed of braided, platinum-cored Nitinol wire (Platinol™ Wire) and features three key components: radial force to help maintain duct patency and resist migration, flexibility to aid in conforming to tortuous anatomies and full-length radiopacity to enhance stent visibility under fluoroscopy. 

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs